Results 131 to 140 of about 141,466 (220)

GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

open access: yesJournal of Internal Medicine, Volume 300, Issue 6, Page 758-778, December 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley   +1 more source

The Circulating Cholangiocarcinoma Protein Biomarkers CRP and MASP2 Also Predict Gallbladder Cancer Risk

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2403-2407, 15 November 2026.
ABSTRACT In a recent publication, Lapitz et al. reported differences in serum levels that predict the development of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis prior to clinical manifestation. We examined whether these biomarkers also predict the risk of gallbladder cancer (GBC) in European prospective plasma samples from ...
Linda Zollner   +4 more
wiley   +1 more source

Shikonin: From Biosynthesis and Pharmacological Mechanisms to Translational Safety and Drug Delivery

open access: yesChemBioChem, Volume 27, Issue 21, 12 November 2026.
Shikonin, biosynthesised in Boraginaceae roots from phenylalanine‐derived PHB and isoprenoid GPP, modulates redox balance, cellular stress, signalling pathways, and regulated cell death. Preclinical studies support diverse pharmacological activities, while nanocarriers improve dispersion and delivery.
Namini Joshi   +6 more
wiley   +1 more source

Benign Neoplasms of the Gallbladder*

open access: yesAnnals Of Surgery, 1960
S F, OCHSNER, A, OCHSNER
openaire   +3 more sources

Liver organoids: modelling complexity in homeostasis and disease

open access: yesFEBS Letters, Volume 600, Issue 21, Page 3265-3285, November 2026.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Intracholecystic papillary neoplasm (ICPN) of gallbladder. a case report [PDF]

open access: yes
In the WHO Classification of Tumours of the Digestive System (2019), intracholecystic papillary neoplasm (ICPN), a pre-invasive neoplasm of the gallbladder, is described as non-invasive epithelial neoplasm with macroscopically discernible mass of pure ...
Mohtarrudin, Norhafizah   +2 more
core   +2 more sources

Intracholecystic Papillary-tubular Neoplasm (ICPN) of the Gallbladder: A Case Report Focusing on an Unexpected Pathological Finding

open access: yes
Background: Intracholecystic papillary neoplasms (ICPNs) represent a rare benign entity characterized by intraluminal polypoid lesions in the gallbladder. The incidence of ICPNs ranges from 0.4% to 0.61% in all gallbladder specimens.
Gafà, Roberta   +6 more
core   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3902-3913, November 2026.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub   +3 more
wiley   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3862-3873, November 2026.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy